89
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Changes in Serum Nesfatin-1 After Laparoscopic Sleeve Gastrectomy are Associated with Improvements in Nonalcoholic Fatty Liver Disease

, , , , & ORCID Icon
Pages 1459-1464 | Published online: 01 May 2020

References

  • Fan JG, Kim SU, Wong VWS. New trends on obesity and NAFLD in Asia[J]. J Hepatol. 2017;67(4):862–873. doi:10.1016/j.jhep.2017.06.003
  • Younossi ZM, Loomba R, Rinella ME, et al. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Hepatology. 2018;68(1):361–371. doi:10.1002/hep.29724
  • Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases[J]. Hepatology. 2018;67(1):328–357.
  • Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)[J]. Metabolism. 2016;65(8):1038–1048. doi:10.1016/j.metabol.2015.12.012
  • Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis[J]. J Hepatol. 2018;68(2):280–295. doi:10.1016/j.jhep.2017.11.014
  • Cernea S, Roiban AL, Both E, et al. Serum leptin and leptin resistance correlations with NAFLD in patients with type 2 diabetes[J]. Diabetes Metab Res Rev. 2018;34(8):e3050. doi:10.1002/dmrr.3050
  • Oh S, Shimizu H, Satoh T, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus[J]. Nature. 2006;443(7112):709. doi:10.1038/nature05162
  • Stengel A, Taché Y. Nesfatin-1—role as possible new potent regulator of food intake[J]. Regul Pept. 2010;163(1–3):18–23. doi:10.1016/j.regpep.2010.05.002
  • Nakata M, Manaka K, Yamamoto S, et al. Nesfatin-1 enhances glucose-induced insulin secretion by promoting Ca2+ influx through L-type channels in mouse islet β-cells[J]. Endocr J. 2011;1102080532.
  • Özsavcí D, Erşahin M, Şener A, et al. The novel function of nesfatin-1 as an anti-inflammatory and antiapoptotic peptide in subarachnoid hemorrhage–induced oxidative brain damage in rats[J]. Neurosurgery. 2011;68(6):1699–1708. doi:10.1227/NEU.0b013e318210f258
  • Merali Z, Cayer C, Kent P, et al. Nesfatin-1 increases anxiety-and fear-related behaviors in the rat[J]. Psychopharmacology. 2008;201(1):115. doi:10.1007/s00213-008-1252-2
  • Jakobsen GS, Småstuen MC, Sandbu R, et al. Association of bariatric surgery vs medical obesity treatment with long-term medical complications and obesity-related comorbidities[J]. JAMA. 2018;319(3):291–301. doi:10.1001/jama.2017.21055
  • Angrisani L, Santonicola A, Iovino P, et al. IFSO worldwide survey 2016: primary, endoluminal, and revisional procedures[J]. Obes Surg. 2018;28(12):3783–3794. doi:10.1007/s11695-018-3450-2
  • Ding L, Sousa KM, Jin L, et al. Vertical sleeve gastrectomy activates GPBAR‐1/TGR5 to sustain weight loss, improve fatty liver, and remit insulin resistance in mice[J]. Hepatology. 2016;64(3):760–773. doi:10.1002/hep.28689
  • Ballestri S, Romagnoli D, Nascimbeni F, et al. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications[J]. Expert Rev Gastroenterol Hepatol. 2015;9(5):603–627. doi:10.1586/17474124.2015.1007955
  • Sberna AL, Bouillet B, Rouland A, et al. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non‐alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes[J]. Diabetic Med. 2018;35(3):368–375. doi:10.1111/dme.13565
  • Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease[J]. Digestive Liver Dis. 2010;42(7):503–508. doi:10.1016/j.dld.2009.08.002
  • Bedogni G, Bellentani S, Miglioli L, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population[J]. BMC Gastroenterol. 2006;6(1):33. doi:10.1186/1471-230X-6-33
  • Satapathy SK, Sanyal AJ. Epidemiology and natural history of nonalcoholic fatty liver disease[C]//Seminars in liver disease. Thieme Med Publishers. 2015;35(03):221–235.
  • Lassailly G, Caiazzo R, Buob D, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients[J]. Gastroenterology. 2015;149(2):379–388. doi:10.1053/j.gastro.2015.04.014
  • Myronovych A, Kirby M, Ryan KK, et al. Vertical sleeve gastrectomy reduces hepatic steatosis while increasing serum bile acids in a weight‐loss‐independent manner[J]. Obesity. 2014;22(2):390–400. doi:10.1002/oby.20548
  • Ramanjaneya M, Chen J, Brown JE, et al. Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity[J]. Endocrinology. 2010;151(7):3169–3180. doi:10.1210/en.2009-1358
  • Prinz P, Stengel A. Expression and regulation of peripheral NUCB2/nesfatin-1. Curr Opin Pharmacol. 2016;31:25–30. doi:10.1016/j.coph.2016.08.012
  • Pan W, Hsuchou H, Kastin AJ. Nesfatin-1 crosses the blood–brain barrier without saturation[J]. peptides. 2007;28(11):2223–2228. doi:10.1016/j.peptides.2007.09.005
  • Yin Y, Li Z, Gao L, et al. AMPK-dependent modulation of hepatic lipid metabolism by nesfatin-1[J]. Mol Cell Endocrinol. 2015;417:20–26. doi:10.1016/j.mce.2015.09.006
  • Wang Y, Li Z, Zhang X, et al. Nesfatin-1 promotes brown adipocyte phenotype[J]. Sci Rep. 2016;6(1):34747. doi:10.1038/srep34747
  • Wu D, Yang M, Chen Y, et al. Hypothalamic nesfatin-1/NUCB2 knockdown augments hepatic gluconeogenesis that is correlated with inhibition of mTOR-STAT3 signaling pathway in rats[J]. Diabetes. 2014;63(4):1234–1247. doi:10.2337/db13-0899
  • Foo KS, Brauner H, Östenson CG, et al. Nucleobindin-2/nesfatin in the endocrine pancreas: distribution and relationship to glycaemic state[J]. J Endocrinol. 2010;204(3):255–263. doi:10.1677/JOE-09-0254
  • Maejima Y, Horita S, Kobayashi D, et al. Nesfatin-1 inhibits voltage gated K+ channels in pancreatic beta cells[J]. Peptides. 2017;95:10–15. doi:10.1016/j.peptides.2017.07.001
  • Lee WJ, Chen CY, Ser KH, et al. Differential influences of gastric bypass and sleeve gastrectomy on plasma nesfatin-1 and obestatin levels in patients with type 2 diabetes mellitus[J]. Curr Pharm Des. 2013;19(32):5830–5835. doi:10.2174/13816128113198880010
  • Moon HS, Dalamaga M, Kim SY, et al. Leptin’s role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals[J]. Endocr Rev. 2013;34(3):377–412. doi:10.1210/er.2012-1053
  • Dalamaga M, Chou SH, Shields K, et al. Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives[J]. Cell Metab. 2013;18(1):29–42. doi:10.1016/j.cmet.2013.05.010
  • Anini Y, Brubaker PL. Role of leptin in the regulation of glucagon-like peptide-1 secretion[J]. Diabetes. 2003;52(2):252–259. doi:10.2337/diabetes.52.2.252
  • Kieffer TJ, Habener JF. The adipoinsular axis: effects of leptin on pancreatic β-cells[J]. Am J Physiol Endocrinol Metab. 2000;278(1):E1–E14. doi:10.1152/ajpendo.2000.278.1.E1